Notable
Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Primary endpoint(s) modified
Also in this update: Enrollment increased: 202 → 228 participants; Trial sites expanded: 18 → 22 locations
Astellas Pharma Korea, Inc.Not specified NCT06011954 Registry history of NCT06011954 on ClinicalTrials.gov (opens the registry)